These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Gender-related issues in the pharmacology of new anti-obesity drugs. Cataldi M; Muscogiuri G; Savastano S; Barrea L; Guida B; Taglialatela M; Colao A Obes Rev; 2019 Mar; 20(3):375-384. PubMed ID: 30589980 [TBL] [Abstract][Full Text] [Related]
6. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Verpeut JL; Bello NT Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397 [TBL] [Abstract][Full Text] [Related]
7. New medications for treatment of obesity: metabolic and cardiovascular effects. Pucci A; Finer N Can J Cardiol; 2015 Feb; 31(2):142-52. PubMed ID: 25661549 [TBL] [Abstract][Full Text] [Related]
8. Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management. Fujioka K; Braverman-Panza J J Fam Pract; 2016 Jul; 65(7 Suppl):S16-23. PubMed ID: 27565106 [TBL] [Abstract][Full Text] [Related]
9. Is cardiometabolic risk improved by weight-loss drugs? Astrup A Lancet; 2010 Aug; 376(9741):567-8. PubMed ID: 20673996 [No Abstract] [Full Text] [Related]
11. Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents. Walter CP; Bleske BE; Dorsch MP J Clin Pharm Ther; 2014 Oct; 39(5):475-84. PubMed ID: 24924286 [TBL] [Abstract][Full Text] [Related]
12. [The pharmacotherapy of obesity]. Budai KA; Mirzahosseini A; Noszál Béla ; Tóth G Acta Pharm Hung; 2015; 85(1):3-17. PubMed ID: 26137782 [TBL] [Abstract][Full Text] [Related]
13. Current and emerging pharmacotherapies for obesity in Australia. Hocking S; Dear A; Cowley MA Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558 [TBL] [Abstract][Full Text] [Related]
14. Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Montan PD; Sourlas A; Olivero J; Silverio D; Guzman E; Kosmas CE Ann Transl Med; 2019 Aug; 7(16):393. PubMed ID: 31555707 [TBL] [Abstract][Full Text] [Related]
15. Drug treatment of obesity: current status and future prospects. Kakkar AK; Dahiya N Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851 [TBL] [Abstract][Full Text] [Related]
17. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. Nissen SE; Wolski KE; Prcela L; Wadden T; Buse JB; Bakris G; Perez A; Smith SR JAMA; 2016 Mar; 315(10):990-1004. PubMed ID: 26954408 [TBL] [Abstract][Full Text] [Related]
18. Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk. Caterson ID; Finer N Asia Pac J Clin Nutr; 2006; 15 Suppl():55-62. PubMed ID: 16928662 [TBL] [Abstract][Full Text] [Related]
19. Drug treatment of obesity in cardiovascular disease. Charakida M; Finer N Am J Cardiovasc Drugs; 2012 Apr; 12(2):93-104. PubMed ID: 22292446 [TBL] [Abstract][Full Text] [Related]